Compare Ascendis Pharma A/S (ASND) vs Carlyle Group Inc (CG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Carlyle Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Carlyle Group Inc trades at $44.71 (market cap $16.09B). The key difference: Ascendis Pharma A/S and Carlyle Group Inc are close in size by market cap, and Carlyle Group Inc pays a 3.13% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CG | |
|---|---|---|
Market Cap | $17.74B | $16.09B |
Sector | Health | Financials |
52-Week High | $277.18 | $69.35 |
52-Week Low | $163.32 | $40.52 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CG trades at $44.71, up 1.2% today, with neutral technical signals and mixed earnings performance. The company reported Q1 2026 EPS of $0.89, missing expectations, but maintains a strong analyst consensus with a $60.33 price target. Recent developments include the acquisition of a majority stake in MAI Capital Management and the upcoming Q2 2026 earnings release on August 5, 2026.
The outlook is cautiously optimistic, supported by analyst bullishness and strategic acquisitions, but risks include volatile cash flows from operations and recent earnings misses. Investment opportunity lies in the significant upside to the consensus price target if execution improves, while downside risks stem from operational cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
